The World Health Organization has discontinued trials of hydroxychloroquine, lopinavir, and ritonavir for the treatment of coronavirus. Officials admitted that the effectiveness of these drugs has not been proven.
The decision to terminate the tests was made after the intermediate test results showed that the mortality rate of patients hospitalized with coronavirus after taking the antimalarial drug practically did not decrease. WHO also stopped testing two other drugs – lopinavir and ritonavir. Doctors admitted that the reduction in inpatient mortality was negligible or even absent.
The National Institute of Health also suspended the hydroxychloroquine test after the study showed no harm or benefit from the use of the antimalarial drug for hospitalized patients with COVID-19.
For safety and efficacy reasons, the US Food and Drug Administration (FDA) has revoked the emergency use of antimalarial hydroxychloroquine and chloroquine.
Denise Hinton, a senior fellow at the U.S. Food and Drug Administration, said the agency would not allow prescribing the drug to hospitalized patients with COVID-19 or use it in clinical trials. Officials said both drugs are “unlikely to be effective”.